Last reviewed · How we verify

Epidural Bupivacaine plus fentanyl

University of Texas Southwestern Medical Center · FDA-approved active Small molecule Quality 2/100

Epidural Bupivacaine plus fentanyl is a Small molecule drug developed by University of Texas Southwestern Medical Center. It is currently FDA-approved. Also known as: Epidural continous infusion of bupivacaine and fentanyl.

At a glance

Generic nameEpidural Bupivacaine plus fentanyl
Also known asEpidural continous infusion of bupivacaine and fentanyl
SponsorUniversity of Texas Southwestern Medical Center
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Epidural Bupivacaine plus fentanyl

What is Epidural Bupivacaine plus fentanyl?

Epidural Bupivacaine plus fentanyl is a Small molecule drug developed by University of Texas Southwestern Medical Center.

Who makes Epidural Bupivacaine plus fentanyl?

Epidural Bupivacaine plus fentanyl is developed and marketed by University of Texas Southwestern Medical Center (see full University of Texas Southwestern Medical Center pipeline at /company/university-of-texas-southwestern-medical-center).

Is Epidural Bupivacaine plus fentanyl also known as anything else?

Epidural Bupivacaine plus fentanyl is also known as Epidural continous infusion of bupivacaine and fentanyl.

What development phase is Epidural Bupivacaine plus fentanyl in?

Epidural Bupivacaine plus fentanyl is FDA-approved (marketed).

Related